3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
48
Prostatic Neoplasms
33
Breast Neoplasms
23
Stomach Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Lung Neoplasms
15
Esophageal Neoplasms
13
Neoplasm Metastasis
11
Sarcoma
9
Neoplasms
9
Colorectal Neoplasms
7
Urinary Bladder Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Transitional Cell
6
Carcinoma, Renal Cell
6
Melanoma
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Carcinoma, Ovarian Epithelial
4
Breast Neoplasms, Male
4
Salivary Gland Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
3
Pancreatic Neoplasms
3
Non-Muscle Invasive Bladder Neoplasms
3
Leiomyosarcoma
3
Inflammatory Breast Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
Docetaxel
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled